Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 1/20 | 0.56 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.56 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.56 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.56 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.56 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.56 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.47 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 8/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1793957 | 1.00 | PRKAB2 (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1787391 | 1.00 | PRKAB2 (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1789874 | 0.96 | PRKAB2 (0.59) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1788522 | 0.91 | PRKAB2 (0.66) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1792187 | 0.91 | PRKAB2 (0.63) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1790863 | 0.86 | PRKAB2 (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1787254 | 0.84 | HRH3 (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1790093 | 0.84 | HRH3 (0.53) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1789163 | 0.84 | PRKAB2 (0.54) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL1790628 | 0.83 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1238005-B1 | ROOM TEMPERATURE VULCANIZABLE SILICONE COMPOSITIONS WITH IMPROVED ADHESION TO ACRYLIC | ALLIED SIGNAL INC (US) | 2004-09-29 | — | — | EP | claimed |
| EP-0127934-B1 | SILOXANE-POLYESTER COMPOSITIONS | Dow Corning Limited (GB) | 1987-01-28 | — | — | EP | claimed |
| EP-0134442-B1 | SILICONE PASTES CURABLE AT ROOM TEMPERATURE | BAYER AG (DE) | 1986-12-30 | — | — | EP | claimed |
| EP-2513271-B1 | LUBRICATING OIL COMPOSITIONS CONTAINING TITANIUM COMPLEXES | CHEVRON ORONITE CO (US) | 2019-10-09 | — | — | EP | disclosed |
| EP-2652098-B1 | METHOD AND USE FOR IMPROVING FLUOROCARBON ELASTOMER SEAL COMPATIBILITY | CHEVRON ORONITE CO (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9062273-B2 | Lubricating oil compositions containing titanium complexes | CHEVRON ORONITE COMPANY LLC (US) | 2015-06-23 | — | — | US | disclosed |
| US-8716202-B2 | Method for improving fluorocarbon elastomer seal compatibility | CHEVRON ORONITE COMPANY LLC (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2652098-A1 | METHOD FOR IMPROVING FLUOROCARBON ELASTOMER SEAL COMPATIBILITY | Chevron Oronite Company LLC (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120309654-A1 | LUBRICATING OIL COMPOSITIONS CONTAINING TITANIUM COMPLEXES | CHEVRON ORONITE COMPANY LLC (US) | 2012-12-06 | — | — | US | disclosed |
| EP-2513271-A2 | LUBRICATING OIL COMPOSITIONS CONTAINING TITANIUM COMPLEXES | Chevron Oronite Company LLC (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2012082285-A1 | METHOD FOR IMPROVING FLUOROCARBON ELASTOMER SEAL COMPATIBILITY | CHEVRON ORONITE COMPANY LLC (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120149618-A1 | Method for improving fluorocarbon elastomer seal compatibility | CHEVRON ORONITE COMPANY LLC (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011081731-A2 | LUBRICATING OIL COMPOSITIONS CONTAINING TITANIUM COMPLEXES | CHEVRON ORONITE COMPANY LLC (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110143980-A1 | Lubricating oil compositions containing titanium complexes | CHEVRON ORONITE COMPANY LLC (US) | 2011-06-16 | — | — | US | disclosed |
| EP-2326625-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-05-26 | — | — | US | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010007382-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HSTAMINE H3 ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED. (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124626-A1 | BENZAZEPINE DERIVATIVES AND THEIR USE AS HISTAMINE H3 ANTAGONISTS | HRH4, HRH3, HRH2 | PRKAB2 4723/4885PRKAG1 4737/4885PRKAA2 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.